Shares of biopharmaceutical company Iovance Biotherapeutics (NASDAQ: IOVA) have been skyrocketing lately. Amtagvi drives significant sales growth for Iovance in Q2On Aug. 6, Iovance released its second-quarter earnings numbers, which showed strong growth for its promising cancer treatment, Amtagvi (lifileucel). In addition to generating significant revenue growth this past quarter, the company also drastically reduced its losses during the period. The stock may even become an attractive acquisition target for a larger healthcare company, given its modest market cap of around $3 billion. This can be an excellent growth stock for investors who are comfortable taking on some risk and uncertainty.